Date:29/11/2021
Your Name: Shaojie Liu
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	Stock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Chao Xu
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	Stock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Keying Zhang
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	Stock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Donghui Han
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	Stock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Fa Yang
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	tock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Yu Li
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	tock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Xiaolong Zhao
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	X None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	_XNone
	testimony	
-	0	
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
_		
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
10	in other board, society,	<u>_x</u> nonc
	committee or advocacy	
11	group, paid or unpaid	W N
11	tock or stock options	_XNone
12	Receipt of equipment,	X None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	X None
13	financial interests	_NNone

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Shanjin Ma
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	_XNone
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert	_XNone
	testimony	
7	Comment for all and the second	<b>V</b>
7	Support for attending meetings and/or travel	_XNone
8	Patents planned, issued or	_ <b>X</b> None
	pending	
0	Double in the control of the	<b>V</b>
9	Participation on a Data Safety Monitoring Board or	_XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	_XNone
12	Receipt of equipment,	_XNone
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	_ <b>X</b> None
	financial interests	

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Hongji Li
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

Consulting fees	_XNone
Payment or honoraria for	_XNone
Payment for expert	X None
testimony	
Support for attending meetings and/or travel	_XNone
	_XNone
pending	
Dorticination on a Data	W N
•	_XNone
Leadership or fiduciary role	X None
in other board, society,	
committee or advocacy group, paid or unpaid	
Stock or stock options	_XNone
	_XNone
services	
	_XNone
financial interests	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Shiqi Lu
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

Consulting fees	_XNone
Payment or honoraria for	_XNone
Payment for expert	X None
testimony	
Support for attending meetings and/or travel	_XNone
	_XNone
pending	
Dorticination on a Data	W N
•	_XNone
Leadership or fiduciary role	X None
in other board, society,	
committee or advocacy group, paid or unpaid	
Stock or stock options	_XNone
	_XNone
services	
	_XNone
financial interests	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Tong Lu
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
Royalties or licenses	_XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Time frame: past  XNone  XNone

Consulting fees	_XNone
Payment or honoraria for	_XNone
Payment for expert	X None
testimony	
Support for attending meetings and/or travel	_XNone
	_XNone
pending	
Dorticination on a Data	W N
•	_XNone
Leadership or fiduciary role	X None
in other board, society,	
committee or advocacy group, paid or unpaid	
Stock or stock options	_XNone
	_XNone
services	
	_XNone
financial interests	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Jiayu Zhang
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

Consulting fees	_XNone
Payment or honoraria for	_XNone
Payment for expert	X None
testimony	
Support for attending meetings and/or travel	_XNone
	_XNone
pending	
Dorticination on a Data	W N
•	_XNone
Leadership or fiduciary role	X None
in other board, society,	
committee or advocacy group, paid or unpaid	
Stock or stock options	_XNone
	_XNone
services	
	_XNone
financial interests	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Weijun Qin
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	_XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	X None
	testimony	<u>_x</u> none
7	Support for attending meetings and/or travel	_XNone
	,	
8	Patents planned, issued or	_XNone
	pending	
9	Dankisia skiana ana Daka	W
9	Participation on a Data Safety Monitoring Board or	_XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	<u>_x</u> none
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_XNone
12	Descipt of anylow sut	Y N
12	Receipt of equipment, materials, drugs, medical	_XNone
	writing, gifts or other	
	services	
13	Other financial or non-	_XNone
	financial interests	

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Weihong Wen
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	_XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	X None
	testimony	<u>_x</u> none
7	Support for attending meetings and/or travel	_XNone
	,	
8	Patents planned, issued or	_XNone
	pending	
9	Dankisia skiana ana Daka	W
9	Participation on a Data Safety Monitoring Board or	_XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	<u>_x</u> none
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_XNone
12	Descipt of anylow sut	Y N
12	Receipt of equipment, materials, drugs, medical	_XNone
	writing, gifts or other	
	services	
13	Other financial or non-	_XNone
	financial interests	

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement:

Date:29/11/2021
Your Name:Bo Yang
Manuscript Title: CD248 as a bridge between angiogenesis and immunosuppression: a promising
prognostic and therapeutic target for renal cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China (No. 81772734)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

4	Consulting fees	_XNone
5	Payment or honoraria for	_XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or educational events	
6	Payment for expert	X None
	testimony	<u>_x</u> none
7	Support for attending meetings and/or travel	_XNone
	,	
8	Patents planned, issued or	_XNone
	pending	
9	Dankisia skiana ana Daka	W
9	Participation on a Data Safety Monitoring Board or	_XNone
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	<u>_x</u> none
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	_XNone
12	Descipt of anylow sut	Y N
12	Receipt of equipment, materials, drugs, medical	_XNone
	writing, gifts or other	
	services	
13	Other financial or non-	_XNone
	financial interests	

The author reports that this study was partly supported by National Natural Science Foundation of China (No.: 81772734).

Please place an "X" next to the following statement to indicate your agreement: